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ABSTRACT
This quality improvement project aimed to drive large 
scale and sustained change to reduce the burden of 
chronic kidney disease in the UK. The intervention is a 
software program that extracts relevant biochemical data 
from laboratory databases which then generate graphs 
of estimated kidney function (eGFR) over time. Graphs 
showing progressive kidney disease are sent directly back 
to general practitioners (GPs) to alert them to rereview 
patient care and if necessary, refer to renal services. The 
aim of this evaluation study was to explain the barriers 
and drivers to implementation and adoption of the eGFR 
graph intervention. This evaluation study involved 5 of 
the 20 participating renal units (sites) . A developmental 
evaluation approach was used. Methods included 
collection of descriptive data about graph reporting; GP 
surveys (n=68); focus groups (n=4) with practices; face- 
to- face interviews with secondary care clinicians (n=10). 
Results showed the mean number of graphs reviewed 
per week per site was 230, taking 1 hour per week per 
site. Only 18.2% graphs highlighted a concerning decline 
in kidney function. Important enablers to sustain the 
intervention were low cost, easy to understand, a sense of 
local ownership and perceived impact. Barriers included 
nephrologists’ perceived increase in new referrals. We 
concluded that developmental evaluation can explain the 
barriers/drivers to implementation of a national quality 
improvement project that involves a variety of different 
stakeholders. The intervention has the potential to slow 
down progression of kidney disease due to the eGFR 
prompts alerting GPs to review the patient record and 
take action, such as reviewing medications and referring 
to renal teams if progressive kidney disease had not been 
identified previously.
INTRODUCTION
Chronic kidney disease (CKD) is a major 
public health issue and stages 3–5 CKD affect 
5%–6% of the adult population in the UK.1 
If CKD remains undetected and untreated, 
progression to more advanced stages has a 
severe impact both on survival and quality 
of life, especially when renal replacement 
therapy (RRT) is required.2 Improved 
identification and management of CKD can 
be improved through better information 
systems.3
Referral of patients with CKD from primary 
to secondary care in the UK is broadly based 
on the international staging of CKD.4 Patients 
with CKD stages 1–3 are generally cared for 
in primary care and referred to secondary 
care if they reach stage 4.5 The inevitable 
result of this approach is that many patients 
with CKD stage 3 that are progressing more 
quickly towards the more advanced stages of 
disease, are not referred until relatively late 
in their progression. Late referral (within 3 
months of requiring dialysis) leads to poorer 
outcomes, such as prolonged hospitalisa-
tion, increased mortality, as well as a lower 
likelihood of planned vascular access or pre- 
emptive kidney transplantation.6
Aims of the project
A programme to Spread eGFR graph Surveil-
lance for the early Identification, Support 
and Treatment of people with progressive 
Chronic Kidney Disease (ASSIST- CKD) aims 
to drive large scale, measurable and sustain-
able change that reduces the burden of CKD 
across the UK, and in particular reduces late 
presentation for RRT.7 In 2017–2018, the 
proportion of patients presenting late to 
secondary care varied across renal units in 
England, Wales and Northern Ireland from 
6.9% to 40.5% (mean 16.1%).8 The recom-
mended preparation time for RRT is 1 year.5
The design of the intervention
The intervention consists of a dedicated 
graphing software program together with 
review of estimated glomerular filtration 
rate (eGFR) graphs by trained staff within 
secondary care.3 The software extracts 
relevant biochemical data from hospitals’ 
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graphs of eGFR over time for patients <65 years with an 
eGFR <50 mL/min/1.73 m2 and patients >65 years with 
an eGFR <40 mL/min/1.73 m2. Individuals who review 
the graphs (laboratory staff, a renal pharmacist or a renal 
nurse) are given virtual training and undertake compe-
tency assessment. For those patients whose graphs show 
a declining eGFR trajectory (as opposed to low but stable 
function) the laboratory sends the eGFR graph to the 
patient’s general practitioner (GP) (family doctor) with 
an alert for them to review kidney function and decide 
if specialist advice is needed. Some sites have more than 
one person involved in the intervention: one person 
undertaking the graph interpretation and another to 
undertake the administrative tasks such as placing the 
graphs into envelopes and posting.
The aim is not to mandate referral to secondary care, 
but simply to highlight individuals that are at high risk 
and thereby increase opportunities to delay progression 
and, where this is not possible, to prepare for RRT in a 
timely fashion. The intervention was previously imple-
mented in one site in 2011 and is considered to be the 
main driver to reducing late presentation in this site.3 
This site now has the lowest late referral rate in the UK 
(6.9% presenting within 90 days before RRT start).8 The 
ASSIST- CKD programme aimed to spread this interven-
tion to 20 sites across the UK. This paper reports on one 
part of the evaluation and was undertaken concurrently 
as the project progressed. A quantitative evaluation will be 
reported in early 2021, with the primary outcome being 
the rate of late presentation, defined as the proportion of 
patients with end- stage kidney disease first seen by renal 
services less than 90 days before commencing RRT. This is 
a key quality metric in kidney disease. Data on late presen-
tation are collected routinely by the UK Renal Registry 
and will be compared across participating sites before 
and after implementation of the intervention. Presenta-
tion, defined as time between first visit with a nephrolo-
gist and start of RRT, will be analysed as a binary outcome, 
with late presentation defined as time <90 days.
The aim of the mixed- method evaluation reported 
in this paper is to investigate the barriers and drivers 
to the adoption and sustainability of the intervention 
in 5 of the 20 intervention sites. As many successful 
interventions which are spread to new settings fail 
to achieve the same impact, or indeed any impact at 
all,9 it is important to identify the barriers and drivers 
to adoption and sustainability, in order to facilitate 
spread to other organisations.
MATERIALS AND METHODS
Developmental evaluation (DE)10 was chosen as the 
evaluation framework as it is suitable for dynamic, 
novel and complex environments that are not suited 
to standard formative and summative evaluation. This 
intervention is dynamic as there were changes made 
to the intervention as a result of the local contexts: 
different countries of the UK (England, Scotland and 
Wales), IT systems and size of population covered by 
the renal unit (305 000–600 000 people). In summary, 
DE can be undertaken where both the path and the 
destination are evolving.
Unlike traditional evaluation, DE sits inside the project, 
therefore, it is necessary for the evaluator to be part of the 
programme development team11 and to recognise, record 
and feedback unexpected and unpredicted outcomes, in 
order to facilitate continuous improvement of a project. 
This happened regularly within this project, during 
project team and evaluation advisory group (EAG) meet-
ings, and also face- to- face feedback from the evaluator, 
such as local results of GP survey/focus groups, to indi-
vidual sites. These 1–1 formal sessions with the evaluator 
occurred twice during the 2- year programme, although 
contact with the project team was much more frequent. 
In addition, the project team ran three learning events, 
whereby sites shared their learning experiences, along-
side open dialogue on best practice methods and review 
challenges. The purpose was to encourage sites to long- 
term adoption, sustainability and independence.
DE explores both fidelity and impact of an interven-
tion. The fidelity of the intervention evaluates the degree 
to which the original intervention has been replicated, 
which in turn contributes to a viable assessment of its 
impact.
The first five sites that had implemented the inter-
vention for >1 year (by January 2017) were included in 
the evaluation. All sites were in England but varied in 
geographical size (305 000–600 000 population). All 
sites implemented the intervention as described above, 
but there were some subtle differences, with one site 
involving a renal nurse in the interpretation of graphs 
instead of laboratory staff, and another with a fully auto-
mated system whereby graphs were reported electroni-
cally to primary care (instead of being sent by mail as was 
the practice in the other intervention sites).
Patient and public involvement
We recruited a diverse team of ten people to our patient 
project team (PPT) and overall individuals contributed 
to the project design and dissemination of the findings, 
including presentation of their powerful personal and 
impactful stories at our collaborative learning events for 
sites; had a major role in developing our business case 
document and infographic for commissioners and repre-
sented the project team at dissemination events. Members 
of the PPT also contributed to the evaluation measures 
including development of the GP survey and discussions 
about whether the showing of eGFR graphs to patients 
might cause harm.
Evaluation methods and outcomes
Evaluation of fidelity
Fidelity is defined in terms of five elements that need to be 
measured: adherence, exposure or dose, quality of delivery, 
participant responsiveness and programme differentia-
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success). Table 1 shows how fidelity was evaluated in each 
of the five sites.
Evaluation of impact
Evaluation of impact was carried out between May and 
July 2018 and comprised either face- to- face or telephone 
interviews with clinical biochemists/renal nurse and 
nephrologists in all sites. These interview questions are 
shown in box 1.
Interviews were taped and transcribed. The interview 
data were analysed manually using thematic analysis.12 
In order to add to the interview data’s trustworthiness,13 
another project team member checked and verified the 
themes and inferences that were emerging.
As with all quality improvement projects, evaluation of 
sustainability is crucial. Our key marker of sustainability 
was that a site had implemented eGFR reporting for more 
than 1 year (ie, reporting for which the sites received no 
funding or support from the project grant. We check that 
eGFR data are sent to the UKRR 3 monthly and that new 




18.2% of reviewed graphs were reported to GPs but there 
was wide variation (9.3%–28.7%), even when the size of the 
population was taken into account (see table 2).
Interpretation of the graphs took approximately 1 hour 
per week per site. The number of graphs reported and 
sent to GPs was stable over time across all sites, apart from 
one site which decreased its reporting rate in year 2, due to 
increasing experience and confidence of the person who 
reviewed the graphs, so there less reporting of decisions 
that are borderline (explained at interview).
Exposure
Only a small number of graphs were received by an indi-
vidual GP practice each month. One site reported 20% of 
cases where no evidence of the eGFR graph being actioned 
could be found.
part of the feedback from one or two GPs was that, 
because it doesn’t say result on it, the receptionist 
wasn’t passing it on… (Nephrologist)
Table 1 Methods of fidelity capture
Adherence to 





Audit: no of graphs 
reviewed 3 monthly




12–18 months poststart 
date
GP survey
Referral rates to 
secondary care 
annually
1–1 interviews with 
nephrologists (project lead 
in each site) 12–18 months 
poststart date
1–1 interviews (box 2) with 
staff who interpret the 
graphs (laboratory staff or 
renal nurse) 12–18 months 
poststart date
Practice focus groups: 
whether graphs are 
received by GPs 12–18 
months poststart date.
Practice focus groups 
12–18 months poststart 
date
4–8 staff, including a 
practice manager, GP(s) 
and practice nurse(s).
Practice focus groups 
12–18 months poststart 
date
The GP survey is shown in (online supplemental material interview) questions are shown in box 2.
GP, general practitioner.
Box 1 Interview questions (Impact/outcomes)
Effectiveness
 ► Have you had any specific cases where progressive chronic kidney 
disease has been stabilised or reversed?
 ► Given the results to date (from the Renal Registry) can you give any 
insights into these results?
 ► Do you think that the ASSIST- CKD (A programme to Spread eGFR 
graph Surveillance for the early Identification, Support and Treatment 
of people with progressive Chronic Kidney Disease) project has im-
pacted on your recent late referral data from the Renal Registry?
 ► What has been better/worse since the project started?
Intended/unintended consequences?
 ► How does/how eGFR surveillance fit in to renal surveillance in your 
area (new developments)?
 ► Have there been any intended/unintended consequences?
Sustainability
 ► Have you any plans for sustainability, for example, personal factors?
 ► Is there a need for a business case/incentivisation for this to 
continue?
 ► Have you thought about succession planning?
 ► Is there a need for further continuous professional development 
(CPD)/training?
Box 2 Interview /focus group questions (fidelity)
 ► Can you explain how you first got involved in the ASSIST- CKD 
(A programme to Spread eGFR graph Surveillance for the early 
Identification, Support and Treatment of people with progressive 
Chronic Kidney Disease) project?
 ► What were the drivers/barriers to getting started?
 ► How has the ASSIST- CKD project been running so far?
 ► What has made it easy/difficult?
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Quality of intervention
A total of 90% GPs in the survey (out of 68 responses) said 
that the eGFR graphs were helpful, even though GP manage-
ment systems in the UK already have the facility to generate 
eGFR graphs. The additional perceived value offered by 
ASSIST may be that the ASSIST intervention actively high-
lights high risk patients to GPs, whereas the graphing facil-
ities within GP software systems only produce graphs on 
request. There is also a potential benefit for patients as the 
graphs can be used to support self- management. One GP 
said:
I show the graphs all the time to patients ……CKD is 
difficult to explain in simple terms, it is not like a cancer 
and it is not in the public eye. So, it is actually difficult 
for them to come to terms with, compared with other 
illnesses.
Responsivenes
Determining whether GPs act on the graphs is impor-
tant but can be challenging, particularly when consid-
ering the variety of activities carried out within the 
practice. However, one clinical scientist found that 
patients who had been flagged often had repeat tests 
showing improved renal function, implying that some 
intervention had taken place. Specific examples of 
where the GPs acted on the graphs included review of 
kidney function, checking that the patient has been 
coded for CKD, and making sure that deteriorating 
kidney function has not been missed.
Differentiation (elements for success)
The ASSIST- CKD software has been continually reviewed 
and adapted in response to the views of the sites to increase 
the speed of the software to make reviewing of past results 
and alerts easier, which has impacted in a positive way on 
the motivation to continue.
In many sites, it was the setup stage that was critical, with 
buy- in from the Medical Director of the hospital, the IT 
Director/manager and IT staff working in the laboratory 
an essential requirement. Another benefit seen when renal 
teams report the graphs is that deterioration in patients 
already known to secondary care is highlighted in advance 
of, or in between, routine clinic visits. As one renal nurse 
said
Most weeks I highlight a change in eGFR in one of our 
patients which can result in them being admitted, or 
being asked to attend for urgent repeat bloods, to have 
their out- patients appointment brought forward, or 
the Consultants sending a letter to their GP regarding 
medication changes…
In summary, the drivers for adoption are that the interven-
tion can be adapted to changing needs, low cost, quick, easy 
to understand and clinicians can clearly see the benefit. 
The barriers are that that there needs to be full buy- in from 
a variety of stakeholders at the start.
Impact findings
The findings are grouped into five main themes. Table 3 
shows the themes and subthemes. Drivers are shown in 
green and barriers are shown in red.






























per 100 000 
population
A 3341.2 1005.6 28.7 222
B Data not 
available
C 4703.3 436.5 9.3 109
D 2269.6 482.8 21.2 80
E 1622.8 218.7 13.6 72




Lack of understanding 
by GPs on type of 
action needed
Action taken by GPs 
(not referral)
Perceived increase 
in new referrals to 
secondary care
Reduction in late 
referrals (not measured 
in this part of the 
evaluation)
Likelihood that 
the intervention is 
impacting on late 
referral
Enhanced surveillance 
of patients either not 
known or known to 
renal
Quality of information on 
referrals to secondary 
care
Positive impact on 
staffing (continuous 
professional 
development (CPD) and 
reflective practice)
Graphs providing safety 
net for nephrologists
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Effectiveness
The GP survey identified that GPs were sometimes unclear 
on what to do following receipt of the graph, with some just 
referring straight back to secondary care without reviewing 
the patient. However, the intervention was never intended 
to give prescriptive advice, but rather to highlight trends to 
GPs to enable them to use their judgement in the light of 
their knowledge of the individual patient. Some GPs liked 
this (as it allows some freedom in decision- making) whereas 
others did not, preferring directed advice.
Impacts
As one nephrologist has outlined there are multiple bene-
fits for patient care that are not directly captured if the 
outcome is simply reduction in late referral.
…there are different levels of benefit. So, the GPs just 
having to review the medication, made a change and 
that’s made a difference. That’s one: I think that’s 
probably the best sort of change that we can effect. 
Then the second is they haven’t but at least they are 
monitored: that’s a second benefit…the third one is 
they have looked at it and now they have referred a 
patient. I think all of that doesn’t get captured if you 
only look at the end point… (Nephrologist)
In one site, 8/13 GPs indicated that they had done ‘some-
thing else’ with 4/8 indicating that they had reviewed 
medication. It is also possible that graphs are reviewed but 
this has not resulted in any action because it might not 
be appropriate, where there are existing conditions such 
as dementia and frailty. One interviewee commented on 
the impact on care of those patients already known to the 
renal team, while a theme that was raised by a number of 
nephrologists was the eGFR graph acting as reassurance 
that patients with progressive CKD were not being missed, 
even if they were referred back to primary care after first 
review.
Unintended consequences
One unintended consequence of the intervention might 
have been an increased number of inappropriate referrals. 
A couple of nephrologists were convinced of the impact 
‘we had to put on a lot of extra clinics’, yet others could 
not be certain. However, new referral data across three 
of the five sites showed no impact (max 1–2 new refer-
rals per month) following initiation of the ASSIST- CKD 
intervention.
One site conducted their own local evaluation into 
referral patterns. Over half the patients who triggered an 
alert had their blood tests repeated. There were only 20% 
where no evidence of the alert being actioned (no bloods 
had been repeated and no referrals made).
As well as the number of referrals that might have 
been impacted because of the ASSIST- CKD project, 
another theme which developed during the interviews 
was the perceived reduction in quality of the information 
supporting the referral.
I would say the first thing is that the nature of the 
referral is poor, it has been generated, so the GPs 
are saying okay you asked for a referral, here is 
the referral, I won’t give you any details about the 
patient’s history, so it’s a very short referral letter 
in general, here is your graph, back to you type of 
referral. (Nephrologist)
Outcomes
A number of interviewees were very positive about the 
potential outcomes of the ASSIST- CKD project. The 
reasons for positivity were anticipated clinical benefit, 
with the prospect of delaying the need for dialysis is some. 
However, one interviewee perceived that the benefit 
outweighed any unintended consequences
I always suspected a hugely increased number of 
referrals but … if we are preventing ten or even 
fifteen these crashing (onto) dialysis, that’s probably 
good. I think—if you look at it—probably preventing 
some going into that stage. (Clinical biochemist)
The initial possible impact of ASSIST- CKD in this site is 
extremely encouraging and is driving the site to sustain 
the intervention for another 2 years, especially as funding 
has been provided to enable this to happen.
Sustainability
The ASSIST- CKD funding only covered 1- year interven-
tion at each site, but all the evaluation sites continued 
implementing well beyond this, especially if the system 
became embedded.
we all felt that it was a good thing to do and we need 
to do it in a manner where it would not be a huge 
additional burden to us and it just gets integrated to 
our routine, clinical work that we do…. it’s very well 
embedded and, as you know, it’s part of our clinical 
validation pathway. (Clinical biochemist)
Table 4 shows the sites, start times and reasons for 
sustaining stopping the intervention.
If the evaluation sites are compared with all the partic-
ipating sites, seven sites have been reporting for more 
than 3 years, 12 sites for 2 years or more and one site has 
been active for just 1 year. However, as of 7 October 2020 
of the 20 sites have stopped reporting, the reasons given 
are as follows:- staffing issues in two sites, IT problems in 
two sites, commissioners withdrew funding in one loca-
tion and COVID-19 has caused a temporary stop in a 
further two sites.
DISCUSSION
This is the first study in primary care in the UK to scale 
up an impactful intervention that concerns identification 
of progressive CKD, using DE to identify the barriers and 
drivers. The drivers to implementation and sustainability 
appear to be the modest time investment (on average 
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support. The evaluation has captured the ‘hidden’ work 
by GPs and highlights the relevance of other actions 
beyond referral to secondary care. In secondary care, the 
drivers are enhanced surveillance of patients either not 
known or known to renal teams, confidence in the ‘safety 
net’, and a possibility that the intervention is impacting 
on late referral.
Lincoln and Guba14 propose the concepts of credi-
bility, transferability, dependability and confirmability to 
address trustworthiness and quality in naturalistic (qual-
itative) inquiry. Credible findings have been generated 
because of our peer debriefing sessions (project team 
meetings), checking our interpretations against raw data 
(data analysed by the Renal Registry statistician) and 
member checking (checking interview data with partici-
pants). To enhance transferability to other sites we have 
provided a detailed description of the sites, context and 
data analysis. Dependability refers to investigators arriving 
independently at the same or similar interpretations. We 
ensured robust communication, particularly at critical 
points, with (external) members of our EAG. Confirm-
ability of findings were assured as data were sourced 
across various settings and locations. For consistency, one 
member of the project team (the evaluator) conducted all 
the interviews and initial coding of the data, but another 
person undertook detailed coding and cross- checked 
back with the evaluator. All members of the project team 
discussed preliminary findings to ensure they were a cred-
ible interpretation of participants’ responses.
Fidelity: lessons learnt
We learnt the importance of continual review and adap-
tation of the software in response to feedback from the 
sites. The greatest challenge in delivery was technical, as a 
result of the highly variable IT landscape across the sites. 
Halfway through the project, in Spring 2016, a radical 
decision was taken to completely recode the software 
with a new commercial (third party) developer to make 
it more efficient, user- friendly and able to support longer- 
term sustainability. This major upgrade was supported 
by the Funder and involved a finite 6- month build time 
and piloting in three National Health Service laboratory 
test sites to ensure reliable and accurate eGFR graphing 
results and speed of performance.
Impact: lessons learnt
While the results of the full quantitative evaluation are 
not yet available, the results of this qualitative evaluation 
suggests the existence of softer benefits beyond any impact 
on headline of late referral, which may only become evident 
after a period of years, for example, review of medication, 
retesting of eGFR, and discussion of self- management with 
the patient. Few interventions have focused on identifica-
tion of those at risk of progressive kidney disease. An Amer-
ican study15 in 11 practices assessed whether clinical decision 
support could be used to improve CKD identification by 
using risk assessment tools, health maintenance protocols, 
flow charts and a patient registry. The authors concluded 
that barriers such as incorporating use of improvement 
tools into existing workflow must be addressed to effectively 
achieve improvements in CKD outcomes. An improvement 
collaborative in the UK16 with tailored facilitation support 
appeared to promote the uptake of evidence- based guid-
ance on the identification and management of CKD in 
primary care. Another UK study17 used trigger tools for 
identifying CKD from the electronic health record, found 
that in addition to these tools identifying patients with a 
falling eGFR, they also prompted review of the eGFR trajec-
tory and management plan, as we found in this evaluation. 
A systematic review18 identified the most common barrier 
Table 4 Sustainability of sites
Site Start date Finish date Reason for sustaining/stopping
A 12.Aug.15 Live Embedded practice into lab weekly work stream
Low cost
Obtained support from commissioners to continue project
Belief in initiative - initial outcome data looks encouraging
B 4.Dec.15 30.Oct.17 Inconsistent implementation
Loss of data due to in- house IT crash
Only one lab clinical scientist to run intervention, whereas a minimum of two people 
required to cover sickness and holidays
C 19.Oct.15 Live Embedded—part of clinical validation pathway
Low cost
Spread initial funding over 2 years
Belief in initiative
D 6.Oct.15 31.Jul.18 Lack of admin support to send letters to GPs
New Trust encryption process for software required—not compatible
E 26.Sep.16 Live Anticipated clinical benefit
Embedded practice into work stream
Modest staff time required to manage system
Fully automated system for reporting results electronically to primary care
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to identification and management of CKD in primary care 
was a lack of time, explaining to patients they had CKD and 
dissatisfaction with CKD guidelines. The most common 
driver, which resonates with our findings, was supportive 
technology and also a collaborative relationship between 
primary and secondary care.
Limitations
We do not have specific details on how GPs responded to 
the graphs, apart from their responses to the survey and 
explanations in the focus groups. Further studies in this 
area are warranted, especially as it is recognised that late 
referral rates to secondary care can be a very blunt instru-
ment for measuring impact.
CONCLUSION
The national intervention has proved feasible even without 
external funding. It has been well received and potentially 
added value. The evaluation identified four important 
enablers that sustain a quality improvement intervention: 
low cost, easy to understand, a sense of local ownership and 
perceived impact. These enablers should be considered 
when developing and sustaining any large- scale interven-
tion in primary care. The intervention has the potential to 
slow down progression of kidney disease due to the eGFR 
prompts alerting GPs to review the patient record and take 
action.
Twitter Nicola Thomas @nicolamthomas
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